0.29
+0.0395(+16.09%)
Currency In USD
| Previous Close | 0.25 |
| Open | 0.25 |
| Day High | 0.29 |
| Day Low | 0.24 |
| 52-Week High | 2.38 |
| 52-Week Low | 0.22 |
| Volume | 31.9M |
| Average Volume | 1.09M |
| Market Cap | 2.53M |
| PE | -0.2 |
| EPS | -1.46 |
| Moving Average 50 Days | 1.07 |
| Moving Average 200 Days | 1.44 |
| Change | 0.04 |
If you invested $1000 in BioRestorative Therapies, Inc. (BRTX) 10 years ago, it would be worth $0.02 as of February 14, 2026 at a share price of $0.285. Whereas If you bought $1000 worth of BioRestorative Therapies, Inc. (BRTX) shares 5 years ago, it would be worth $3.96 as of February 14, 2026 at a share price of $0.285.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
BioRestorative Announces Closing of $5.0 Million Public Offering
GlobeNewswire Inc.
22 hours ago
MELVILLE, N.Y., Feb. 13, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a late stage clinical regenerative medicine innovator focused on stem cell-based therapies and products, tod
BioRestorative Announces Pricing of $5.0 Million Public Offering
GlobeNewswire Inc.
Feb 12, 2026 3:30 AM GMT
MELVILLE, N.Y., Feb. 11, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a late stage clinical regenerative medicine innovator focused on stem cell-based therapies and products, tod
BioRestorative Announces Positive Outcome from Type B Meeting with FDA
GlobeNewswire Inc.
Feb 11, 2026 12:30 PM GMT
BioRestorative completed a Type B meeting with the U.S. Food and Drug Administration (“FDA”) regarding a potential accelerated Biologics License Application (“BLA”) approval pathway for the Fast-Track-Designated BRTX-100 program for the treatment of